Why does null hypothesis testing matter for DHT pellet-induced PCOS models?

Null hypothesis testing in the DHT pellet-induced PCOS model enables rigorous evaluation of androgen-driven phenotypes, supporting target validation and mechanistic clarity. This approach reduces biological ambiguity and informs early-stage portfolio decisions. Reliable hypothesis testing underpins confidence in downstream translational research.

How does independent variable isolation fit the DHT pellet workflow?

Isolating DHT exposure as the independent variable ensures that observed phenotypes are attributable to androgen excess, strengthening mechanistic insights. This isolation is critical for discovery-stage de-risking and for establishing causality in endocrine research pipelines. It supports reproducibility and cross-study comparability.

What do quantitative dependent variable measurements enable in this PCOS model?

Quantitative measurement of metabolic and reproductive endpoints enables objective assessment of disease phenotypes and intervention effects. These outputs facilitate data-driven go/no-go decisions and support cross-functional evaluation of therapeutic hypotheses. Quantitative data also enhance predictive confidence for translational advancement.

Why do replication requirements matter for DHT pellet-based studies?

Replication ensures that observed effects are robust and reproducible across cohorts, which is essential for cross-functional collaboration and portfolio confidence. Standardized pellet preparation and dosing protocols support consistent results, enabling reliable comparison of interventions. Replication underpins the credibility of preclinical findings.

What statistical analysis capabilities are required before implementing DHT pellet models?

Robust statistical analysis is needed to compare phenotypic outcomes between DHT-treated and control groups, assess variability, and validate significance. Analytical rigor ensures that model outputs inform actionable R&D decisions and support regulatory or translational milestones. Statistical capabilities are foundational for model adoption in enterprise workflows.

Subcutaneous Dihydrotestosterone (DHT) Treatment: Mouse Model of Polycystic Ovary Syndrome (PCOS)

JoVE Encyclopedia of Experiments

Biology

0 views • 3:53 min • April 30th, 2023

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

First, to prepare the pellet, inject medical adhesive silicone down one end of a pre-cut piece of silicone tubing. Next, pack dihydrotestosterone or DHT crystal powder tightly inside the tubing. Then, use medical adhesive silicone to seal the other end of the tubing. Pellets should have equal amounts of silicone at each end with no bubbles. Place pellets in saline solution before inserting them in a female mouse.

On an anesthetized mouse, use a cotton swab with disinfectant to clean the shaved surgical area. Make a small incision through the skin near the neck. Use a trochar to make a tunnel under the skin in the direction of the mouse's nose. Insert the pellet into the tunnel. Lastly, seal the incision with surgical adhesive. The pellet will release a steady dose of DHT and is replaced every 4 weeks to ensure prolonged exposure to the drug.

For dihydrotestosterone or DHT pellet preparation, use a razor blade to cut a 15-millimeter piece of silicone tubing and use a 3-milliliter syringe equipped to a blunted 20-gauge needle to inject 2 to 5 millimeters medical adhesive silicone into one end of the tube. Allow the tubing to dry overnight and check for air bubbles on the sealed end.

Wearing the appropriate personal protective equipment, pour DHT powder into a plastic weigh boat in a flow hood. Impress the open end of the adhesive-capped tube into the powder. Using a large straightened paper clip, tamp the powder down into the tubing until the DHT reaches the appropriate experimental depth. Then, seal the open side of the tube with silicone overnight.

The next morning, cut each sealed side to obtain a 2-millimeter length of silicone on both sides of the DHT and no DHT control pellets. Then, store the pellets in a 50-milliliter conical tube wrapped with foil at room temperature for up to 3 months.

For PCOS mouse model generation, equilibrate up to 20 DHT or control pellets in separate 50-milliliter conical tubes containing 30 milliliters of 0.9% saline for 24 hours at 37 degrees Celsius. The next day, confirm a lack of response to toe pinch in an anesthetized 2-month-old female mouse and use sterile gauze to administer sequential povidone-iodine and 70% ethanol scrubs to the surgical area.

Next, make a 5-millimeter incision through the skin near the neck and use a 10-gauge trochar to make a 15-millimeter tunnel in the rostral direction. Use the trochar to insert a pellet dorsally into the tunnel and seal the incision with the surgical adhesive. Manually approximate the wound edges with forceps and use gentle brushing strokes to apply 3 thin film layers of liquid adhesive to 1 centimeter out from each side of the apposed wound edges.

Then, place the mouse alone in a cage on a heat pad with monitoring until full recumbency, replacing the pellet every 4 weeks to maintain a constant level of androgen exposure.